Effect of Lavandula Officinalis in treatment of diabetes

Study of the Effect of Hydroalcholic Extract of Lavandula Officinalis on Some Biochemical Factors in Blood and Urine in Diabetes.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200826048534N1

Enrollment

Registered

2020-09-12

Start date

2019-05-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Diabetes mellitus

Interventions

Intervention 1: Intervention group: 40 diabetic patients who, in addition to routine medications used by diabetic patients (Metformin, Glibenclamide), received 2, 500 mg capsules containing Lavender e

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of diabetes Patients aged 30 to 60 years Fasting blood sugar =126 mg / dl Intravenous blood serum glucose 200 mg/dl, 2 hours after ingestion of 75 g of oral glucose Not receiving insulin HbA1C from 7 to 8.5 Diagnosis of diabetes is less than 10 years Use only oral antihyperglycemic drugs(Metformin,Glibenclamide)

Exclusion criteria

Exclusion criteria: Smoking Chronic Cardiovascular Diseases Chronic Kidney Disease Triglycerides more than 500 Pregnancy Taking Anticoagulants (except Aspirin) Chronic Liver Diseases except Fatty Liver Advanced Diabetic Retinopathy Kidney Failure Heart Failure Hemorrhagic Stroke

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;HbA1C. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Cholestrol. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Very low density lipoprotein. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Low density lipoprotein. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;High density lipoprotein. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Triglyceride. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Alanine transaminase. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Aspartate aminotransferase. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Blood urea nitrogen. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Creatinine. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Urine sugar. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: Wi	—

Measure

Time frame

Fasting blood sugar. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;HbA1C. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Cholestrol. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Very low density lipoprotein. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Low density lipoprotein. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;High density lipoprotein. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Triglyceride. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Alanine transaminase. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Aspartate aminotransferase. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Blood urea nitrogen. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Creatinine. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: With special kits by an autoanalyzer system.;Urine sugar. Timepoint: At the beginning of the study and 2 months after consumption of drugs. Method of measurement: Wi

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Mahmudnia

Shahre-kord University of Medical Sciences

mahmudnia.L@skums.ac.ir+98 38 3333 9940

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026